JPMorgan Chase & Co. Reiterates Neutral Rating for Sanofi (SNY)

JPMorgan Chase & Co. reaffirmed their neutral rating on shares of Sanofi (NYSE:SNY) in a research note released on Thursday.

A number of other research analysts also recently issued reports on the company. Bank of America downgraded Sanofi from a buy rating to a neutral rating in a research note on Wednesday, December 6th. Zacks Investment Research downgraded Sanofi from a hold rating to a strong sell rating in a research note on Friday, October 6th. Morgan Stanley downgraded Sanofi from an overweight rating to an underweight rating in a research note on Friday, December 1st. Barclays upgraded Sanofi from an underweight rating to an equal weight rating in a research note on Wednesday, November 15th. Finally, Cowen set a $48.00 price target on Sanofi and gave the stock a hold rating in a research note on Monday, December 18th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $51.50.

Sanofi (NYSE SNY) traded up $0.77 during trading hours on Thursday, reaching $44.78. The company had a trading volume of 1,659,800 shares, compared to its average volume of 1,292,944. The stock has a market cap of $111,950.00, a P/E ratio of 20.35, a PEG ratio of 2.58 and a beta of 0.86. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. Sanofi has a 12-month low of $39.42 and a 12-month high of $50.65.

Sanofi (NYSE:SNY) last released its quarterly earnings results on Thursday, November 2nd. The company reported $1.00 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.00. Sanofi had a return on equity of 25.19% and a net margin of 25.44%. equities research analysts predict that Sanofi will post 3.3 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. Moors & Cabot Inc. lifted its position in Sanofi by 0.7% during the 2nd quarter. Moors & Cabot Inc. now owns 6,494 shares of the company’s stock worth $311,000 after acquiring an additional 43 shares during the period. Strategic Global Advisors LLC lifted its position in Sanofi by 0.6% during the 2nd quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock worth $414,000 after acquiring an additional 54 shares during the period. First City Capital Management Inc. lifted its position in Sanofi by 0.3% during the 2nd quarter. First City Capital Management Inc. now owns 38,389 shares of the company’s stock worth $1,839,000 after acquiring an additional 100 shares during the period. Toronto Dominion Bank lifted its position in Sanofi by 4.6% during the 2nd quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock worth $195,000 after acquiring an additional 180 shares during the period. Finally, Logan Capital Management Inc. lifted its position in Sanofi by 1.6% during the 2nd quarter. Logan Capital Management Inc. now owns 19,095 shares of the company’s stock worth $915,000 after acquiring an additional 294 shares during the period. 9.08% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/jpmorgan-chase-co-reiterates-neutral-rating-for-sanofi-sny/1838154.html.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August


Leave a Reply

 
© 2006-2018 BBNS.